Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Effect of Xerostomia on the Functional Capacity of Subjects with Rheumatoid Arthritis

Marília Lins e Silva, Camila Nunes Carvalho, Alessandra de Albuquerque Tavares Carvalho, Jair Carneiro Leão, Angela Luzia Pinto Duarte and Luiz Alcino Gueiros
The Journal of Rheumatology October 2016, 43 (10) 1795-1800; DOI: https://doi.org/10.3899/jrheum.151211
Marília Lins e Silva
From the Oral Medicine Unit, Department of Clinical and Preventive Dentistry, and the Rheumatology Unit, Clinics Hospital, Federal University of Pernambuco, Recife, Brazil.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camila Nunes Carvalho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandra de Albuquerque Tavares Carvalho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jair Carneiro Leão
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela Luzia Pinto Duarte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luiz Alcino Gueiros
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: luiz.mgueiros@ufpe.br
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To evaluate the intensity of xerostomia and hyposalivation in subjects with rheumatoid arthritis (RA) as well as the effects of these conditions on functional incapacity and disease activity.

Methods. The study sample comprised 236 individuals of both sexes who had RA. All the individuals were submitted to clinical evaluation and unstimulated sialometry. Functional capacity was determined by using the Health Assessment Questionnaire (HAQ), xerostomia was assessed using the Xerostomia Inventory, and disease activity was evaluated with the 28-joint Disease Activity Score (DAS28). The effect of Sjögren syndrome (SS) was analyzed, and the sample was divided into 2 groups: RA (191 subjects) and RA/SS (45 subjects).

Results. The Xerostomia Inventory showed positive and significant correlation with fatigue (r = 0.243; p < 0.0001), number of painful joints (r = 0.218; p = 0.001), HAQ (r = 0.279; p < 0.0001), and DAS28 (r = 0.156; p < 0.0001). On regression analysis, both xerostomia (OR 3.89, 95% CI 1.84–8.23, p < 0.001) and DAS28 (for severe disease activity: OR 13.26, 95% CI 3.15–55.79, p < 0.001) showed influence on functional incapacity. Forty-five individuals (19.1%) presented with secondary SS, and having this diagnosis was not associated with disease activity or functional capacity.

Conclusion. Xerostomia demonstrated an adverse effect on quality of life of subjects with RA, being associated with a reduction in functional capacity. In this clinical setting, xerostomia can be monitored as a marker of worse clinical evolution.

Key Indexing Terms:
  • XEROSTOMIA
  • RHEUMATOID ARTHRITIS
  • SJÖGREN SYNDROME
  • FUNCTIONAL CAPACITY

Xerostomia is defined as a subjective complaint of dry mouth usually associated with qualitatively or quantitatively changed saliva production. In addition to the dry mouth, xerostomic subjects frequently mention symptoms such as burning mouth; increasing thirst; losing taste sensation; difficulty swallowing, chewing, and speaking; mouth-breathing; tooth sensitivity; gastroesophageal reflux; and poorly fitting removable dentures1,2,3. The prevalence of xerostomia may vary widely, ranging from 4% to 29% in the general population, and is more commonly observed in women and older individuals4.

Although the reduced salivary flow rates are an important aspect of xerostomia, some subjects complain of dry mouth in spite of having normal salivary flow5; therefore we need to evaluate adequately both subjective and objective questions in this group. An instrument called the Xerostomia Inventory has been introduced to determine the effect of xerostomia on day-to-day activities. To our knowledge, it is the first scientifically validated instrument for investigating the prevalence of xerostomia6. On the other hand, the analysis of hyposalivation is based on the objective assessment of the salivary flow rate through sialometry, commonly accepted as a simple and reproducible diagnostic method7.

Rheumatoid arthritis (RA) is a multisystemic, progressive, chronic inflammatory disease, associated with a series of extraarticular manifestations. Xerostomia and hyposalivation are more prevalent in individuals with rheumatic diseases, and may significantly limit the patient’s quality of life8,9,10. Particularly in RA, studies have considered xerostomia and hyposalivation extraarticular manifestations of the disease, although studies have demonstrated that these conditions usually point toward the diagnosis of secondary SS (sSS)3,11,12,13,14.

In addition to oral symptoms, subjects with RA experience high levels of pain, functional incapacity, reduced capacity for work, and premature death15. They develop more constant and higher levels of fatigue in comparison with the population in general16. Even in its initial stage, RA and its extraarticular manifestations have a considerable effect on health-related quality of life, promoting a broad spectrum of functional limitations that may alter daily life activities. Different indicators describe functional capacity of subjects with RA; among them, the Health Assessment Questionnaire (HAQ) has been widely used and scientifically approved17,18. It can provide support for planning alternative strategies for treatment of the disease, thus making it possible to improve quality of life and well-being.

The aim of our study was to evaluate the effect of xerostomia, hyposalivation, and SS diagnosis in subjects with RA and the association of these conditions with functional incapacity and disease activity.

MATERIALS AND METHODS

Sample characterization

An observational epidemiologic study was conducted from March to September 2014, with 236 individuals of both sexes, over the age of 18 years, and with a diagnosis of RA. The sample size was estimated based on the prevalence of xerostomia in subjects with RA, defined as 18.6% in a study conducted by Haga, et al19. The set CI was 95%, with a sampling error of 5%, and an estimated prevalence of 18.6%, resulting in a sample of at least 233 subjects. All the subjects came from the Rheumatology Unit of Hospital das Clínicas — Universidade Federal de Pernambuco (HC-UFPE). Those involved in the research previously consented to their inclusion in the study by signing the Term of Free and Informed Consent, after the study was approved by the Research Ethics Committee of UFPE, protocol No. CCAE 10221112.3.0000.5208.

The diagnosis of RA was based on the criteria determined by the American College of Rheumatology20, and the diagnosis of sSS was established by the criteria of the American-European Consensus Group21. Subjects excluded from the study were those with a history of radiotherapy in the head and neck region, human immunodeficiency virus infection, sarcoidosis, amyloidosis, graft-versus-host disease, hepatitis C virus infection, and use of anticholinergic drugs. All the subjects in the sample were initially evaluated, without separating the subjects with RA only from those with RA/SS.

Functional capacity evaluation

Functional capacity was determined using the HAQ. The instrument developed by Fries, et al17, and translated and validated for Portuguese by Ferraz, et al22 evaluates the functional status of subjects with RA by detecting the level of difficulty the subjects experience when performing day-to-day activities, and their need for assistance to perform them. For each of the 8 categories, the subject indicated the degree of difficulty using 4 possible responses ranging from “no difficulty = 0” to “incapable of doing it = 3”. The score for each category was the highest result of any of its items. The final HAQ score was determined by the mean score of the 8 categories.

Visual analog scales (VAS) were also used, ranging from 0 to 100 mm to evaluate the self-perception of general status (VAS of a general state of disease) and fatigue in the previous week, informed by the subject23.

Xerostomia evaluation

Xerostomia was evaluated by using the Xerostomia Inventory proposed by Thomson, et al5, and validated in Portuguese24. The inventory is composed of 11 items evaluated through a Likert scale ranging from 1 to 5. The sum of the subject’s responses could range from 11 to 55, and higher values corresponded to a more pronounced perception of xerostomia.

Salivary flow rate evaluation

Saliva to evaluate resting salivary flow (RSF) was collected by obtaining whole nonstimulated saliva. Collection occurred according to the previously developed method25. The examination was performed in the afternoon, between 2 PM and 5 PM, and the subjects were instructed not to eat, drink, or smoke for a minimum period of 90 min before saliva collection. After being comfortably seated, the subjects were directed to move the head slightly forward, swallow, and then allow saliva to run from the mouth into a plastic receptacle marked in millimeters, for 15 min. The RSF rate was determined by the total value, divided by 15, and was expressed in milliliters per minute. Values below 1.5 ml (or 0.1 ml/min) were considered positive.

Disease activity evaluation

Disease activity was evaluated using the Disease Activity Score 28 (DAS28). DAS28 uses 28 articulations to count the number of painful and edematous joints, with the erythrocyte sedimentation rate or C-reactive protein as an inflammatory marker, in addition to the overall patient-performed evaluation of health or disease activity, on a scale from 0 to 10026.

According to the result obtained, the subject was considered in remission (< 2.6), low activity (≥ 2.6 to ≤ 3.2), moderate activity (> 3.2 to ≤ 5.1), or intense RA activity (> 5.1).

Statistical analyses

For data analysis, the absolute distributions, percentages, and statistical measures were obtained from the following: mean ± SD and median (descriptive statistics techniques). The Mann-Whitney U test was used for independent samples and the Pearson correlation coefficient for measurement of the linear relationship between the continuous variables.

Regression analysis included all subjects and was performed to evaluate the variables associated with functional incapacity. Functional capacity (HAQ) was introduced as a dependent variable. These were introduced as independent variables: age, duration of disease, VAS of the general state of disease, VAS of fatigue, painful articulations, edematous articulations, disease activity (DAS28), SS diagnosis, xerostomia, Xerostomia Inventory, and salivary flow. Logistic regression was performed by backward LR method. Composing the model involved the variables that had significance ≤ 0.20 in the bivariate analysis, and all tests were applied with 95% CI.

The data obtained for each variable evaluated were recorded, tabulated, and analyzed in a spreadsheet in the SPSS (Statistical Package for the Social Sciences) Software program, version 20.0 for Windows. The level of significance used in the decision of statistical tests was 5.0%.

RESULTS

Clinical characteristics

Two hundred thirty-six subjects were included in the study, of whom the majority were women (94.6%). The median age was 53.32 years (SD 11.93), with a minimum age of 22 years and a maximum of 80 years. The mean disease duration up to the time of interview was 9.47 years (SD 7.98), and a large portion of subjects (38.1%) presented with moderate disease activity. The mean RSF was 0.36 ml/min (SD 0.3 ml/min), ranging from 0.0 to 1.60 ml/min. A mean HAQ value of 1.25 (SD 0.83) was measured, ranging from 0 to 3.0. The mean xerostomia score was 23.62 (SD 10.57), ranging from 11.0 to 53.0. Forty-five individuals (19.1%) presented with the diagnosis of sSS. Table 1 shows the clinical data of the participants in our study. Table 2 describes the drug consumption according to the diagnosis of SS. Antihypertensives and antidepressants were more commonly reported among RA/SS individuals (p = 0.001 and p = 0.033, respectively).

View this table:
  • View inline
  • View popup
Table 1.

Clinical characteristics of sample of 236 patients with rheumatoid arthritis. Results are mean (± SD) unless otherwise indicated.

View this table:
  • View inline
  • View popup
Table 2.

List of reported drugs according to the diagnosis of Sjögren syndrome. Patients with inadequate information regarding medication intake were not included.

Effect of salivary flow and xerostomia

Salivary flow diminished with increase in age (r = −0.160; p = 0.014), and with an increase in the Xerostomia Inventory scores (r = −0.234; p < 0.0001). The Xerostomia Inventory showed positive and significant correlation with the variables: fatigue (r = 0.243; p < 0.0001), number of painful joints (r = 0.218; p = 0.001), HAQ (r = 0.279; p < 0.0001), and DAS28 (r = 0.156; p < 0.0001; Table 3). In addition, 70 individuals (29.7%) complained of xerostomia despite of presenting a normal salivary flow rate (p < 0.0001).

View this table:
  • View inline
  • View popup
Table 3.

Correlation between variables of rheumatoid arthritis and xerostomia.

Effect of sSS diagnosis

Age was not shown to differ between the groups evaluated (RA 52.7 yrs, SD 12.3; RA/SS 56.0 yrs, SD 10.8; p = 0.111). Similarly, the time of RA diagnosis did not vary between the groups (RA 9.3 yrs, SD 7.9; RA/SS 10.6 yrs, SD 7.9; p = 0.217).

Subject resting salivary flow was shown to be significantly reduced in Group RA/SS (RA/SS 0.1 ± 0.1 ml/min × RA 0.4 ± 0.3 ml/min, p < 0.0001), as shown in Table 4. Subjects with RA/SS presented higher Xerostomia Inventory scores (RA 21.7 ± 9.5; RA/SS 31.6 ± 11.2; p < 0.0001).

View this table:
  • View inline
  • View popup
Table 4.

Effect of Sjögren syndrome (SS) diagnosis on clinical presentation of rheumatoid arthritis (RA).

Functional capacity evaluation

The regression model was capable of demonstrating the risk of developing moderate to severe functional incapacity, represented by HAQ > 1. Xerostomia, the number of painful joints, and disease activity (DAS28) remained in the model and were related to HAQ (Table 5). Patients with xerostomia presented an OR 3.89 of developing a moderate to grave functional incapacity (p < 0.001). In addition, the risk of developing HAQ > 1 was increased according to the rise of disease activity, so that patients with elevated RA activity had an OR of developing moderate to severe functional incapacity of 13.26 (p < 0.001).

View this table:
  • View inline
  • View popup
Table 5.

Final regression analysis model highlighting the association between HAQ and RA clinical markers.

DISCUSSION

Undeniably, studies about the diagnostic and prognostic indicators of RA have progressed considerably in the last few years. In spite of this, few studies have related the functional incapacity present in RA to oral symptoms. Our study evaluated the clinical significance of assessing the intensity of xerostomia and resting salivary flow and their effect on the functional capacity of subjects with RA, as well as the correlation between these indicators and the diagnosis of SS. We verified that functional incapacity in the subjects with RA was related to their perception of dry mouth.

RA, because of its chronic inflammatory nature, is a disease that can cause significant morbidity and mortality associated with joint damage, in addition to extraarticular manifestations27. Its symptoms mainly manifest in individuals from 30 to 40 years, although individuals of any age may be affected, including children. The disease may be incapacitating and painful, and may substantially affect mobility as a result of edema, pain, and articular destruction if not treated adequately28. The chief extraarticular manifestations include vasculitis, neuropathy, pericarditis, keratoconjunctivitis sicca, scleritis, episcleritis, peripheral ulcerative keratitis, nephritis, rheumatoid lung disease, amyloidosis, and rheumatoid nodules29. These manifestations appear to represent an indicator of damage or a marker of disease activity, in addition to worse prognosis, greater functional incapacity, and increased mortality30,31. Among the extraarticular manifestations, the symptoms of dry mouth are related to disease activity and subject health status27.

Xerostomia is defined as a subjective perception of dry mouth frequently associated with an accentuated reduction in salivary flow32,33. In this context, resting salivary flow varies according to the presence of xerostomia, so that the Xerostomia Inventory score increased with the reduction in flow24, as we observed. However, many subjects with RA complain of xerostomia in spite of presenting a normal salivary flow rate27,34,35, similar to our findings.

In spite of being considered an extraglandular manifestation of RA, xerostomia may occur owing to additional causes such as sSS32,36,37. SS is a chronic systemic inflammatory disorder that mainly affects the endocrine glands, leading to xerostomia and xerophthalmia. It is characterized by the infiltration of mononuclear cells into the exocrine glands and acinar and ductal destruction, with consequent glandular hypofunction38. The prevalence of SS in subjects with RA has varied from 4% to 40%19,39,40, with this variation possibly being related to the diagnostic criteria, the nationality of the subjects, and tests used. In any event, SS has been associated with a more severe presentation and worse prognosis of RA41,42.

In addition to the symptoms of dryness, studies have shown evidence that the presence of SS demonstrated a possible increased risk of non-Hodgkin lymphoma43, and increased mortality in subjects with RA42,44. Studies have also suggested that the symptoms of dryness are associated with high activity of RA41, and have demonstrated a correlation between hyposalivation and increase in RA activity27. Our present study found an association between RA activity, xerostomia, and the diagnosis of sSS, so that subjects with RA/SS showed a higher number of painful and edematous joints and higher HAQ scores. These findings reinforce the need for diagnosis of SS, to characterize a more aggressive phenotype of RA.

However, few studies have evaluated the risk factors associated with the development of dry mouth and dry eyes in subjects with RA. Wolfe and Michaud reviewed a population of 9921 subjects with RA and observed that the disease activity and treatment contributed to the establishment of oral and ocular symptoms, and that these were related to an increase in HAQ, the number of painful articulations, and fatigue45. The present study observed a correlation between HAQ and the general state, fatigue, number of painful and edematous joints, DAS28, and the Xerostomia Inventory, but only the latter variables accounted for about 40% of the variation in HAQ. Nevertheless, the intensity of xerostomia has a limited influence on this process, as opposed to the greater influence exerted by disease activity as measured through DAS28. Correlation of the HAQ values with improvement in various physical variables in RA allows us to determine the concept of minimally clinical important difference. In our study, we observed that the change of 1 point in DAS28 is capable of promoting a clinically significant change of 0.26 points in HAQ, because the reduction of 0.22 points is indicative of an improvement in the functional status46,47.

Extraarticular manifestations demonstrated an adverse effect on quality of life and prognosis of subjects with RA, with a more steady evolution of the disease, intensification of disease activity, and reduction in functional capacity. Therefore, when implementing actions with the aim of improving the quality of life of these subjects, not only functional capacity but also the intensity of xerostomia and hyposalivation, as well as early diagnosis of SS, should be considered. Also, we emphasize the importance of using self-reported questionnaires, such as the Xerostomia Inventory and HAQ, to guide clinical management, document changes in the subject’s health status, and evaluate the results of treatments.

Footnotes

  • Funded by Pernambuco State Research Foundation (FACEPE – APQ 1978–4.02/12) and the Brazil National Council for Scientific and Technological Development/CNPq (481469/2012-5).

  • Accepted for publication June 30, 2016.

REFERENCES

  1. 1.↵
    1. Humphrey SP,
    2. Williamson RT
    . A review of saliva: normal composition, flow, and function. J Prosthet Dent 2001;85:162–9.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Guggenheimer J,
    2. Moore PA
    . Xerostomia: etiology, recognition and treatment. J Am Dent Assoc 2003;134:61–9; quiz 118–9.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Patinen P,
    2. Aine L,
    3. Collin P,
    4. Hietanen J,
    5. Korpela M,
    6. Enckell G,
    7. et al.
    Oral findings in coeliac disease and Sjogren’s syndrome. Oral Dis 2004;10:330–4.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Pajukoski H,
    2. Meurman JH,
    3. Halonen P,
    4. Sulkava R
    . Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:641–9.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Thomson WM,
    2. Chalmers JM,
    3. Spencer AJ,
    4. Williams SM
    . The Xerostomia Inventory: a multi-item approach to measuring dry mouth. Community Dent Health 1999;16:12–7.
    OpenUrlPubMed
  6. 6.↵
    1. van der Putten GJ,
    2. Brand HS,
    3. Schols JM,
    4. de Baat C
    . The diagnostic suitability of a xerostomia questionnaire and the association between xerostomia, hyposalivation and medication use in a group of nursing home residents. Clin Oral Investig 2011;15:185–92.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Thomson WM,
    2. van der Putten GJ,
    3. de Baat C,
    4. Ikebe K,
    5. Matsuda K,
    6. Enoki K,
    7. et al.
    Shortening the xerostomia inventory. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:322–7.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Pace-Balzan A,
    2. Cawood JI,
    3. Howell R,
    4. Lowe D,
    5. Rogers SN
    . The Liverpool Oral Rehabilitation Questionnaire: a pilot study. J Oral Rehabil 2004;31:609–17.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Baker SR,
    2. Pankhurst CL,
    3. Robinson PG
    . Utility of two oral health-related quality-of-life measures in patients with xerostomia. Community Dent Oral Epidemiol 2006;34:351–62.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Braam PM,
    2. Roesink JM,
    3. Raaijmakers CP,
    4. Busschers WB,
    5. Terhaard CH
    . Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy. Radiat Oncol 2007;2:3.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Ishijima T,
    2. Koshino H,
    3. Hirai T,
    4. Takasaki H
    . The relationship between salivary secretion rate and masticatory efficiency. J Oral Rehabil 2004;31:3–6.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Kaufman I,
    2. Schwartz D,
    3. Caspi D,
    4. Paran D
    . Sjogren’s syndrome — not just Sicca: renal involvement in Sjogren’s syndrome. Scand J Rheumatol 2008;37:213–8.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. de Souza TR,
    2. Carvalho AA,
    3. Duarte AP,
    4. Porter SR,
    5. Leao JC,
    6. Gueiros LA
    . Th1 and Th2 polymorphisms in Sjogren’s syndrome and rheumatoid arthritis. J Oral Pathol Med 2014;43:418–26.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Oliveira HF,
    2. de Souza TR,
    3. Carvalho CN,
    4. Duarte A,
    5. Carvalho AT,
    6. Leão JC,
    7. et al.
    Serologic profile and clinical markers of Sjögren syndrome in patients with rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol 2015;119:628–35.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Hochberg MC,
    2. Johnston SS,
    3. John AK
    . The incidence and prevalence of extraarticular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008;24:469–80.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Repping-Wuts H,
    2. Fransen J,
    3. van Achterberg T,
    4. Bleijenberg G,
    5. van Riel P
    . Persistent severe fatigue in patients with rheumatoid arthritis. J Clin Nurs 2007;16:377–83.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Fries JF,
    2. Spitz P,
    3. Kraines RG,
    4. Holman HR
    . Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Bruce B,
    2. Fries JF
    . The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23 Suppl 39:S14–8.
    OpenUrlPubMed
  19. 19.↵
    1. Haga HJ,
    2. Naderi Y,
    3. Moreno AM,
    4. Peen E
    . A study of the prevalence of sicca symptoms and secondary Sjogren’s syndrome in patients with rheumatoid arthritis, and its association to disease activity and treatment profile. Int J Rheum Dis 2012;15:284–8.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Vitali C,
    2. Bombardieri S,
    3. Jonsson R,
    4. Moutsopoulos HM,
    5. Alexander EL,
    6. Carsons SE,
    7. et al.
    Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Ferraz MB,
    2. Oliveira LM,
    3. Araujo PM,
    4. Atra E,
    5. Tugwell P
    . Crosscultural reliability of the physical ability dimension of the health assessment questionnaire. J Rheumatol 1990;17:813–7.
    OpenUrlPubMed
  23. 23.↵
    1. Pincus T,
    2. Sokka T
    . Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol 2003;17:753–81.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. da Mata AD,
    2. da Silva Marques DN,
    3. Freitas FM,
    4. de Almeida Rato Amaral JP,
    5. Trindade RT,
    6. Barcelos FA,
    7. et al.
    Translation, validation, and construct reliability of a Portuguese version of the Xerostomia Inventory. Oral Dis 2012;18:293–8.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Navazesh M,
    2. Kumar SK;
    3. University of Southern California School of Dentistry
    . Measuring salivary flow: challenges and opportunities. J Am Dent Assoc 2008;139 Suppl:35S–40S.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. van der Heijde DM,
    2. van ‘t Hof MA,
    3. van Riel PL,
    4. Theunisse LA,
    5. Lubberts EW,
    6. van Leeuwen MA,
    7. et al.
    Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916–20.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Uhlig T,
    2. Kvien TK,
    3. Jensen JL,
    4. Axell T
    . Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:415–22.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Smith HS,
    2. Smith AR,
    3. Seidner P
    . Painful rheumatoid arthritis. Pain Physician 2011;14:E427–58.
    OpenUrlPubMed
  29. 29.↵
    1. Turesson C,
    2. Jacobsson LT
    . Epidemiology of extraarticular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004;33:65–72.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Brun JG,
    2. Madland TM,
    3. Jonsson R
    . A prospective study of sicca symptoms in patients with rheumatoid arthritis. Arthritis Rheum 2003;49:187–92.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Carmona L,
    2. Gonzalez-Alvaro I,
    3. Balsa A,
    4. Angel Belmonte M,
    5. Tena X,
    6. Sanmarti R
    . Rheumatoid arthritis in Spain: occurrence of extraarticular manifestations and estimates of disease severity. Ann Rheum Dis 2003;62:897–900.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Hopcraft MS,
    2. Tan C
    . Xerostomia: an update for clinicians. Aust Dent J 2010;55:238–44.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Visvanathan V,
    2. Nix P
    . Managing the patient presenting with xerostomia: a review. Int J Clin Pract 2010;64:404–7.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Moen K,
    2. Bertelsen LT,
    3. Hellem S,
    4. Jonsson R,
    5. Brun JG
    . Salivary gland and temporomandibular joint involvement in rheumatoid arthritis: relation to disease activity. Oral Dis 2005;11:27–34.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Nederfors T,
    2. Holmstrom G,
    3. Paulsson G,
    4. Sahlberg D
    . The relation between xerostomia and hyposalivation in subjects with rheumatoid arthritis or fibromyalgia. Swed Dent J 2002;26:1–7.
    OpenUrlPubMed
  36. 36.↵
    1. Mignogna MD,
    2. Fedele S,
    3. Lo Russo L,
    4. Lo Muzio L,
    5. Wolff A
    . Sjogren’s syndrome: the diagnostic potential of early oral manifestations preceding hyposalivation/xerostomia. J Oral Pathol Med 2005;34:1–6.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Nagler RM,
    2. Salameh F,
    3. Reznick AZ,
    4. Livshits V,
    5. Nahir AM
    . Salivary gland involvement in rheumatoid arthritis and its relationship to induced oxidative stress. Rheumatology 2003;42:1234–41.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Tzioufas AG,
    2. Tatouli IP,
    3. Moutsopoulos HM
    . Autoantibodies in Sjogren’s syndrome: clinical presentation and regulatory mechanisms. Presse Med 2012;41:e451–60.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Fox RI
    . Sjogren’s syndrome. Lancet 2005;366:321–31.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Drosos AA,
    2. Lanchbury JS,
    3. Panayi GS,
    4. Moutsopoulos HM
    . Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum 1992;35:745–8.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Young A,
    2. Koduri G
    . Extraarticular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:907–27.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Martens PB,
    2. Pillemer SR,
    3. Jacobsson LT,
    4. O’Fallon WM,
    5. Matteson EL
    . Survivorship in a population based cohort of patients with Sjogren’s syndrome, 1976–1992. J Rheumatol 1999;26:1296–300.
    OpenUrlPubMed
  43. 43.↵
    1. Kauppi M,
    2. Pukkala E,
    3. Isomaki H
    . Elevated incidence of hematologic malignancies in patients with Sjogren’s syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997;8:201–4.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Turesson C,
    2. O’Fallon WM,
    3. Crowson CS,
    4. Gabriel SE,
    5. Matteson EL
    . Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002;29:62–7.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Wolfe F,
    2. Michaud K
    . Prevalence, risk, and risk factors for oral and ocular dryness with particular emphasis on rheumatoid arthritis. J Rheumatol 2008;35:1023–30.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Russell AS
    . Quality-of-life assessment in rheumatoid arthritis. Pharmacoeconomics 2008;26:831–46.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Wolfe F,
    2. Pincus T,
    3. Fries J,
    4. Greenwood M,
    5. Doyle D
    . Usefulness of the HAQ in the clinic. Ann Rheum Dis 2001;60:811.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 43, Issue 10
1 Oct 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of Xerostomia on the Functional Capacity of Subjects with Rheumatoid Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effect of Xerostomia on the Functional Capacity of Subjects with Rheumatoid Arthritis
Marília Lins e Silva, Camila Nunes Carvalho, Alessandra de Albuquerque Tavares Carvalho, Jair Carneiro Leão, Angela Luzia Pinto Duarte, Luiz Alcino Gueiros
The Journal of Rheumatology Oct 2016, 43 (10) 1795-1800; DOI: 10.3899/jrheum.151211

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Effect of Xerostomia on the Functional Capacity of Subjects with Rheumatoid Arthritis
Marília Lins e Silva, Camila Nunes Carvalho, Alessandra de Albuquerque Tavares Carvalho, Jair Carneiro Leão, Angela Luzia Pinto Duarte, Luiz Alcino Gueiros
The Journal of Rheumatology Oct 2016, 43 (10) 1795-1800; DOI: 10.3899/jrheum.151211
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

XEROSTOMIA
RHEUMATOID ARTHRITIS
SJÖGREN SYNDROME
FUNCTIONAL CAPACITY

Related Articles

Cited By...

More in this TOC Section

  • One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
  • Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases
  • The Positive Predictive Value of a Very High Serum IgG4 Concentration for the Diagnosis of IgG4-Related Disease
Show more Article

Similar Articles

Keywords

  • XEROSTOMIA
  • rheumatoid arthritis
  • Sjögren syndrome
  • FUNCTIONAL CAPACITY

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire